Insider Selling: Gilead Sciences Director Sells 45,000 Shares of Stock (GILD)
Gilead Sciences (NASDAQ:GILD) Director Nicholas G. Moore sold 45,000 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $90.56, for a total value of $4,075,200.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of research firms have recently commented on GILD. Analysts at Maxim Group raised their price target on shares of Gilead Sciences from $112.00 to $127.00 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Thursday, July 24th. They now have a $110.00 price target on the stock, up previously from $100.00. Finally, analysts at Piper Jaffray raised their price target on shares of Gilead Sciences to $111.00 in a research note on Thursday, July 24th. One investment analyst has rated the stock with a hold rating and nineteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $101.63.
Shares of Gilead Sciences (NASDAQ:GILD) traded up 0.94% during mid-day trading on Wednesday, hitting $93.8666. The stock had a trading volume of 8,901,679 shares. Gilead Sciences has a one year low of $55.96 and a one year high of $93.25. The stock’s 50-day moving average is $85.38 and its 200-day moving average is $79.88. The company has a market cap of $143.2 billion and a P/E ratio of 21.07.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the company posted $0.50 earnings per share. The company’s quarterly revenue was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $7.67 EPS for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.